Article
Two large retrospective cohort studies presented by the team at Mayo Clinic, Rochester MN examine the burden of stroke, as well as overall and cause-specific mortality in people with RA (POS0591 and POS0592).
All News
Md Yuzaiful Md Yusof
Tweet
#EULAR2024 OP0288 Patients with Scleroderma shouldn’t be excluded from Lung Transplantation because of a concern with post-surgery complications/long term complications. Data from Italy of N=13 pts showed 93% survival, improved disesase activity & FVC over 2 years @RheumNow https://t.co/zPFB1MFxdc
Mrinalini Dey
Tweet
➡️OP0127- Can we predict who will get persistently active disease in people with palindromic rheumatism (PR)?
📊Cohort of 161 PR
❗️Predictive factors: Female gender, CCP, RF, >40yo, smoking & interval between flares of <1m ➡️ may be used to risk stratify
@RheumNow #EULAR2024
Peter Nash
Tweet
beautiful work Univ of Qld - rat SpA model bacterial dna into entheses blocked by 23i not 17i @RheumNow #EULAR2024 https://t.co/X9hzkA56d0
Dr. Antoni Chan
Tweet
Différent stages of RA with disease progression. McInnes M #EULAR2024 @RheumNow https://t.co/iKpggGYU0k
Md Yuzaiful Md Yusof
Tweet
#EULAR2024 OP0256 Phase 2 RCT ReSScue data of fecal microbiota transplantation did not meet primary endpoint (bloating & diarrhoea) in scleroderma. How about impact on faecal incontinence symptoms? This improved throughout 20wks. Could be due improved stool consistency @RheumNow https://t.co/1t7d3M5S4Z
Dr. Antoni Chan
Tweet
The fracture risk with glucocorticoids is dose dependent. Lems W #EULAR2024 @RheumNow https://t.co/TGjKu1vfXx
Md Yuzaiful Md Yusof
Tweet
#EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ikaros) was well tolerated with
efficacy signal (SLEDAI-2K & CLASI-50). Effect and safety profile were numerically better in the lowest dose @RheumNow https://t.co/Bjk9zBRmVo
Aurelie Najm
Tweet
PsA: one composite index that does it all
cDAPSA + Investigator’s Global Assessment (IGA) of PSO
Cohen’s kappa 0.72 & 88% concordance with PASDAS LDA
88% sensitivity & specificity in DISCOVER-1 & 2 trial data
#EULAR2024 @RheumNow POS0254 https://t.co/ZBb1M4IusC
Aurelie Najm
Tweet
🚨 New 68Ga-FAPI-04-PET/CT, fibroblast activation tracer
38 PSO patients w/ arthralgia
Correlation PET/CT SUVmax, TJC & tender enthesis count
68Ga-FAPI-04 uptake = higher risk developing PsA 6mo
Shows signs of inflammation before MSUS!
#EULAR2024 @RheumNow POS0242 https://t.co/GG6qeD4qJn
Janet Pope
Tweet
Leflunomide for #PMR?
✅ #Leflunomide FAR more effective than #MTX in #polymyalgia #rheumatica
V fast withdrawal of #prednisone
#LEF ~4 to 5 months
#MTX 30 mos!
⬇️flares w LEF
😮
#EULAR2024 @RheumNow @eular_org
@SebaUltraTrail https://t.co/2hk0yMH6gY
Bella Mehta
Tweet
Some of these drugs dont seem to work in all of knee OA. I guess its really difficult to tease out different subtypes.
Subgroup analysis from a Phase 3 intraarticular JTA-004 injection at #EULAR2024 abst#Op0305 @RheumNow https://t.co/jbkLYyl93e
Mrinalini Dey
Tweet
🧠POS0730 Self-reported cognitive function in older adults with #SLE in @ndb_org registry
➡️Cognitive symptoms significantly worse in older people w SLE vs other #RMDs
➡️Perceptions of cognitive function assoc with less satisfaction with health & ⬇️ #QoL
@RheumNow #EULAR2024
Dr. Antoni Chan
Tweet
Check point inhibitors may cause bone loss and fractures. Lems W #EULAR2024 @RheumNow https://t.co/rf1AU60Eah
Dr. Antoni Chan
Tweet
This can be coming to a clinic near you. Hotspot/ROI ratio (HRR) values from high-resolution thermographic marker in the detection of joint inflammation, compared to joint ultrasound showed excellent performance in the differentiation of joints with US inflammatory activity from… https://t.co/1unRxxgHAd https://t.co/tOPDSxzvwB
David Liew
Tweet
Does TCZ switch off GCA histopathologically?
GCA pts still on TCZ (median 2.4y duration) had repeat temporal artery biopsy (contralat)
Despite serological remission on TCZ, a heap had active histopath findings & PET still active. Scary
#EULAR2024 OP0233 Reggio Emilia @RheumNow https://t.co/TKBUP5p4R0
Dr. John Cush
Tweet
RheumNow’s expanded coverage of the #EULAR2024 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our faculty.
Dr. John Cush
Tweet
Greatest chance of sustained drug-free remission (DFR) is seen in early RA pts, NEVER requiring a biologic (esp if seronegative blue line). ERA on biologics never achieve DFR (yellow). Leiden EAC clinic study of 627 ERA pts Abstr# POS0615 #EULAR2024 https://t.co/zpCG6oSE3T
Bella Mehta
Tweet
Loved the talk on #VEXAS by @maferradastrong today at #EULAR2024 !
Amazing pictures to explain cellular level pathophysiology!
Look for abnormal signs that arent otherwise explained to try to get to the diagnosis. @rheumnow https://t.co/YZmAqmFHpE
Md Yuzaiful Md Yusof
Tweet
#EULAR2024 POS0529 Post-hoc analysis from Phase 2 NOBILITY showed consistent renal response was achieved in Obinutuzumab + SOC vs PBO + SOC across Complete Renal Response definitions and baseline Proteinuria levels. Assuring and looking forward to results next year @RheumNow https://t.co/wKCOP5BgoQ
